Discover 524 paid clinical trials in Calgary, . Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Calgary runs one of the busiest research programs in western Canada, with hundreds of studies recruiting at any given time.The Arthur J.E. Child Comprehensive Cancer Centre opened in Calgary in October 2024, making cancer research the city's fastest-growing trial area. Roughly a third of Calgary's recruiting studies are in oncology, and the rest cluster around heart failure, kidney disease, and metabolic conditions, much of it run through the University of Calgary. The city is also unusual for the volume of paediatric research at Alberta Children's Hospital, so families often find studies here that are not available elsewhere in the province.
Filter
2
Filter results
Results: 524
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Calgary, Edmonton, Vancouver, Seattle WA, Vancouver WA,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06943872
Phase3, Recruiting
Implementing REmote SymPtom mOnitoring and maNagement (RESPONd)
for
Cancer
Location: Calgary, Red Deer, Edmonton
Sponsor: University of Calgary
Sex: All
Age: 18+
Code: NCT07024329
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
for
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic,
Location: Calgary, Bozeman MT, Billings MT, Olympia WA,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07144280
Phase3, Recruiting
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
for
Gynecologic Cancer, Anemia, Iron-deficiency
Location: Calgary
Sponsor: AHS Cancer Control Alberta
Sex: Female
Age: 18+
Code: NCT05407987
Phase3, Recruiting
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Location: Calgary, Spokane WA, Denver CO, La Jolla CA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT04728893
Phase2, Recruiting
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
for
Metastatic Colorectal Cancer
Location: Calgary, Saskatoon, Regina, Los Alamitos CA,
Sponsor: Amgen
Sex: All
Age: 18+
Code: NCT06252649
Phase3, Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)